Released Aug 3, 2017, after the close
10-Q filed Aug 3, 2017, 34 days after period end · 0001171843-17-004694
Q2 2017 · 10-Q
Revenue$18.96M$18.96M −27.5% vs Q2 2016+4.8% vs Q1 2017
Net Income-$381.00K-$381.00K N/M vs Q2 2016N/M vs Q1 2017
EPS Diluted-$0.01-$0.01 N/M vs Q2 2016N/M vs Q1 2017
Gross Profit$9,073,000−22.3%
Operating Income-$269,000N/M
Operating Cash Flowderived$475,000−49.6%
Free Cash Flowderived$236,000—
Margins · derived
Gross margin47.9%+3.2 pt vs Q2 2016
Operating margin-1.4%+1.8 pt vs Q2 2016
Net margin-2.0%+0.7 pt vs Q2 2016
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2017 | Q2 2016 | Q2 2015 | Q2 2014 |
|---|---|---|---|---|
| Revenue | $18.96M | $26.14M | $28.80M | $26.96M |
| Net Income | -$381.00K | -$713.00K | $349.00K | $1.02M |
| EPS Diluted | -$0.01 | -$0.02 | $0.01 | $0.03 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Harvard Bioscience Inc · CIK 1123494 · Engraved from SEC EDGAR